A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Abstract Background Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the function of latter. TIGIT (T cell immunoreceptor with Ig and ITIM domains)...
Main Authors: | Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya, Cyrille J. Cohen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0721-y |
Similar Items
-
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01) -
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01) -
ImmunoPET imaging of TIGIT in the glioma microenvironment
by: Sarah R. Vincze, et al.
Published: (2024-03-01) -
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
by: Hauke Stamm, et al.
Published: (2019-12-01) -
Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy
by: Jieqiong WU, et al.
Published: (2022-11-01)